Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model

Veronica Tisato, Chiara Garrovo, Stefania Biffi, Francesca Petrera, Rebecca Voltan, Fabio Casciano, Germana Meroni, Chiara Agnoletto, Giorgio Zauli, Paola Secchiero

Research output: Contribution to journalArticle

Abstract

Ovalbumin (OVA)-sensitized BALB/c mice were i.n. instilled with recombinant TNF-related apoptosis inducing ligand (TRAIL) 24 hours before OVA challenge. The total number of leukocytes and the levels of the chemokine CXCL-1/KC significantly increased in the bronchoalveolar lavage (BAL) fluids of allergic animals with respect to control littermates, but not in the BAL of mice i.n. pretreated with recombinant TRAIL before OVA challenge. In particular, TRAIL pretreatment significantly reduced the BAL percentage of both eosinophils and neutrophils. On the other hand, when TRAIL was administrated simultaneously to OVA challenge its effect on BAL infiltration was attenuated. Overall, the results show that the i.n. pretreatment with TRAIL down-modulated allergic airway inflammation.

Original languageEnglish
Article numbere115387
JournalPLoS One
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 15 2014

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model'. Together they form a unique fingerprint.

  • Cite this

    Tisato, V., Garrovo, C., Biffi, S., Petrera, F., Voltan, R., Casciano, F., Meroni, G., Agnoletto, C., Zauli, G., & Secchiero, P. (2014). Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model. PLoS One, 9(12), [e115387]. https://doi.org/10.1371/journal.pone.0115387